<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00756249</url>
  </required_header>
  <id_info>
    <org_study_id>11767A</org_study_id>
    <secondary_id>2006-005959-15</secondary_id>
    <nct_id>NCT00756249</nct_id>
  </id_info>
  <brief_title>Safety Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke</brief_title>
  <official_title>Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of Lu AA24493 in Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to determine whether carbamylated erythropoietin (CEPO)
      is a safe treatment for patients who have suffered an acute ischemic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute ischemic stroke is a major cause of death and severe disability. There is only one
      approved pharmacological treatment, Alteplase, which has to be administered within 3 hours
      from symptom onset. Consequently, only about 2-3% of patients world wide with ischemic
      strokes are treated. The naturally occurring hormone, erythropoietin (EPO), is able to
      protect various neuronal tissues from ischemic injury and is beneficial in animal models of
      acute ischemic stroke. However, treatment of stroke with EPO is undesirable due to its
      ability to stimulate production of red blood cells and to promote the blood to coagulate. Lu
      AA24493 is a modified (carbamylated) version of EPO, neuroprotective but without the
      haematopoietic side effects. Lu AA24493 is developed for treatment of patients with acute
      ischemic stroke.

      In this safety study of single doses with Lu AA24493, patients will receive Lu AA24493 within
      12-48 hours from symptom onset.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>National Institutes of Health Stroke Scale (NIHSS) and the modified Rankin Scale (mRS)</measure>
    <time_frame>Baseline, Day 7, Day 30; for NIHSS also Day 2 and 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics, immunogenicity and mechanistic biomarkers (S-100b, glial fibrillary acidic protein (GFAP), matrix metalloproteinase 9 (MMP-9))</measure>
    <time_frame>Baseline, Day 1-4, Day 7 and Day 30</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Lu AA24493 (CEPO): 0.005 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lu AA24493 (CEPO): 0.05 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lu AA24493 (CEPO): 0.5 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lu AA24493 (CEPO): 5.0 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lu AA24493 (CEPO): 50.0 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AA24493 (CEPO)</intervention_name>
    <description>0.005 - 50.0 mcg/kg body weight, IV, within 12-48 hrs from symptom onset</description>
    <arm_group_label>Lu AA24493 (CEPO): 0.005 mcg/kg</arm_group_label>
    <arm_group_label>Lu AA24493 (CEPO): 0.05 mcg/kg</arm_group_label>
    <arm_group_label>Lu AA24493 (CEPO): 0.5 mcg/kg</arm_group_label>
    <arm_group_label>Lu AA24493 (CEPO): 5.0 mcg/kg</arm_group_label>
    <arm_group_label>Lu AA24493 (CEPO): 50.0 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vials with solution for IV infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 50 and 90 years

          -  Clinical diagnosis of acute ischemic stroke

          -  Measurable stroke-related deficit

          -  Patient is stable

          -  Treatment can be initiated between 12 hours and 48 hours after the onset of stroke

          -  Expected hospital stay of at least 72 hours after study medication

          -  If female then not of childbearing potential

        Exclusion Criteria:

          -  Primary intracerebral haemorrhage (ICH), or parenchymal haemorrhagic transformation of
             infarction (type PHI or PHII as defined in ECASS), subarachnoid haemorrhage (SAH),
             arterio-venous malformation (AVM), cerebral aneurysm, or cerebral neoplasm

          -  Treated with a thrombolytic &lt;24 hours (if &gt;24 hours excluded ICH then eligible)

          -  Score &gt;0 on the NIHSS item 1a

          -  Pre-stroke mRS score &gt;1

          -  Uncontrolled hypertension

          -  Previous treatment with erythropoietin

          -  Clinically significant abnormal ECG

          -  Cerebral pathology

          -  Received or donated blood within previous 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FI004</name>
      <address>
        <city>Helsinki</city>
        <zip>00029 HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR002</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NL005</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SG003</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB001</name>
      <address>
        <city>Glasgow</city>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2008</study_first_submitted>
  <study_first_submitted_qc>September 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2008</study_first_posted>
  <last_update_submitted>September 24, 2010</last_update_submitted>
  <last_update_submitted_qc>September 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>H. Lundbeck A/S</name_title>
    <organization>H. Lundbeck A/S</organization>
  </responsible_party>
  <keyword>Acute ischemic stroke</keyword>
  <keyword>Erythropoietin</keyword>
  <keyword>Carbamylated</keyword>
  <keyword>Neuroprotection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

